Benzinga's Top Pre-Market Gainers

Celgene (NASDAQ: CELGZ) moved up 100.84% to $6.25 in the pre-market session. Celgene's pancreatic cancer drug Abraxene improved overall survival rates in a phase III study.

Titanium Metals (NYSE: TIE) surged 42.61% to $16.50 in the pre-market session. Precision Castparts (NYSE: PCP) announced its plans to acquire Titanium Metals for around $2.9 billion.

Jefferies Group (NYSE: JEF) added 20.51% to $17.16 in the pre-market session. Leucadia National (NYSE: LUK) announced its plans to acquire Jefferies Group.

Gilead Sciences (NASDAQ: GILD) soared 9.77% to $71.36 in the pre-market trading. Gilead Sciences announced positive results in mid-stage hepatitis C virus (HCV) infection study.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.